<a href="https://www.fiercebiotech.com/biotech/asco-10-billion-ambitions-celcuity-details-breast-cancer-win-over-piqray" hreflang="en">ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray</a>
Celcuity's gedatolisib has shown promising results in doubling progression-free survival for patients with advanced hormone-receptor-positive, HER2-negative breast cancer, outperforming Novartis' Piqray in a recent trial. The biotech company aims to leverage these results for FDA approval and potentially grow into a $10 billion entity by targeting the PAM pathway, crucial for various cancers.
Celcuity's recent ASCO presentation highlighted that their PAM pathway inhibitor, gedatolisib, significantly improved progression-free survival in breast cancer patients compared to Novartis' Piqray, with a safety profile that may offer advantages in dosing and reduced side effects. As Celcuity prepares for FDA approval, this could signal a strong investment opportunity in a company poised to expand its market presence, potentially reaching a valuation of $10 billion if ongoing trials are successful.